I]β-CIT SPECT imaging study A core feature of acute administration of opioid drugs of abuse is their activation of brain dopaminergic neurons and increase in striatal dopamine (DA) release (Di Chiara and Imperato, 1988; Wise et al., 1995) . With more chronic administration, compensatory changes begin to occur, such as downregulation of DA receptors, transporters and function (Spampinato et al., 1988; Simantov, 1993; Wang et al., 2008) that may promote continued use of opioid drugs. Lower DA transporter availability has been reported in imaging studies in recently detoxified heroin users (Jia et al., 2005) and former heroin users with prolonged abstinence (Shi et al., 2008 ) compared with controls. However, a postmortem study found no difference in striatal DA transporter levels between actively using heroin users and controls (Kish et al., 2001) .
The effects of heroin on serotonin (5-HT) function are not as well researched. Acute opiate administration enhances 5-HT activity (Spampinato et al., 1985; Desole et al., 1996) ; however, the effects of prolonged opiate use on 5-HT activity are not clear. In postmortem brain of chronic heroin users, striatal levels of 5-HT were slightly elevated, whereas levels of the serotonin metabolite 5-hydroxyindoleacetic acid were significantly decreased compared with levels in controls (Kish et al., 2001) , suggesting 5-HT activity may be reduced after prolonged use.
In this study, we used [ 123 I]β-CIT and single photon emission computed tomography (SPECT) brain imaging to measure DA and 5-HT transporter availability in chronic heroin users and healthy controls. [ 123 I] β-CIT binds with high affinity to the presynaptic striatal DA and brainstem and diencephalon 5-HT transporters (Laruelle et al., 1993) with high test-retest reliability (Seibyl et al., 1996 (Seibyl et al., , 1997 . We hypothesized lower DA and 5-HT transporter availability in subjects with chronic heroin dependence vs. healthy controls.
Methods

Subjects
Eight heroin-dependent subjects (37.0 ±9.1 years; age range 23-47; 7 men, 1 woman; 6 Caucasian, 2 Hispanic) and eight healthy controls (38.0 ±9.4 years; age range 26-54; 6 men, 2 women; 8 Caucasian) provided informed consent to participate in the study. Groups were matched for age and smoking status (2 heroin and 2 control subjects were nonsmokers). Eligibility was determined as follows: no use of psychotropic drugs within 3 months prior to the study, no lifetime use of the designer drug "ecstasy" (MDMA), and no significant psychiatric, neurological, or medical problems as determined by physical and psychiatric examinations. Heroin-dependent subjects met the DSM-III-R diagnostic criteria for heroin dependence, had at least a 1-year history of 
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